Issuu on Google+

Unique Device for Knee Arthritis Funded

A New Option for Arthritis Pain Sufferers? Visit our website for more arthritis treatment options: http://arthritistreatmenttoday.com


Apos Medical and Sports Technology Ltd., an Israeli company, recently announced that it has raised $8 million in venture capital funding for further development and marketing of its unique device designed for osteoarthritis treatment for knee pain sufferers. The investor is Pitango Venture Capital, Israel’s leading Venture Capital fund. The firm has previously invested in over 120 ventures, including many successful, now publicly traded, companies. The device, which looks like an athletic shoe with two half balls stuck to the bottom, is designed to treat knee osteoarthritis by creating multi-directional instability. The APOS system (short for “All Phases of Step Cycle”) was designed by Dr. Avi Elbaz and Dr. Amit Mor in Israel, and has been in development for the better part of a decade. The arthritis treatment device is a platform attached to a person’s shoes. The balls create instability, which mimics natural walking on uneven surfaces. While counterintuitive, the forced instability strengthens the patient’s muscles and ultimately relieves pain. Treatments take 30 to 60 minutes per day. As the patient uses the device, the instability forces the patient’s body to a proper alignment, reducing pain. Additionally, the patient’s muscles are gradually reeducated, instilling improved patterns of motion for improved function. The treatment is administered by specially trained physiotherapists, and includes computerized gait analysis. The system has been clinically proven to both improve the patient’s gait and alleviate knee pain and other leg joint pain. The key to the system is to focus on functional rehabilitation. While current rehabilitation methods teach a patient how to stand in a clinic, the APOS system simulates real life conditions. The company’s aim was to simulate the way mammals rehabilitated in nature and evolution. The company’s past studies conclude that the treatment can • • •

reduce the intensity of knee pain by 66% after eight weeks eliminate the need for pain relief for lower back pain sufferers in seven out of 10 cases significantly improve joint function, enhancing patients’ quality of life

Drs. Mor and Elbaz have treated over 20,000 patients to date with the device, with about half the treatments in Israel. Additionally, in 2009, the company jointly conducted a commercial trial in the United Kingdom with Bupa, Britain’s largest private health insurance company. The trial culminated in the launch of AposTherapy as an independent entity, which is now a member of the Association of British Healthcare Industries. Apos CEO Dr. Amit Mor says, "The product has several applications. It can be used for stabilization, improve athletes' performance, and prevent knee injury." Brought to you by http://ArthritisTreatmentToday.com


The device can also treat knee damage caused by aging, or injuries from sports or accidents. So far, Apos markets its product in Israel, Singapore, and the UK, where it operates with Britain's largest private health insurance company BUPA Ltd. Apos intends to use the proceeds from Pitango’s investment to finance the launch of its device in other countries, especially the US, Germany, and Japan. The company is seeking to obtain US Food and Drug Administration (FDA) approval as quickly as possible.

Brought to you by http://ArthritisTreatmentToday.com


Visit our website for more arthritis treatment options: http://arthritistreatmenttoday.com

Brought to you by http://ArthritisTreatmentToday.com


Unique Device for Knee Arthritis Funded